Showing the single result
-
Anti-Neutralizing Antibodies (NAbs) Gene Therapies-Pipeline Analytics 2022
$2,700.00 – $8,100.00Anti-Neutralizing Antibodies (NAbs) Gene Therapies report covers the Anti-Neutralizing Antibodies (NAbs) Gene Therapies market opportunity providing Key Competitive Analysis, 20+ Companies with Pipeline Drug Profiles, Clinical Trials, Other Developments (Collaboration Details, Funding, etc.), Licensing and Agreements, Business Agreement, Business Partner as well as Clinical Partner. Reports covers pipeline product analysis by stage of development, competitive landscape by phases, companies, therapy area and indication by phases. NAbs inhibitor’s reports add a value in terms of providing the description of clinical stage product with respect to their clinical & regulatory timelines as well as in terms of providing the current market opportunity, drivers and challenges.
Product Search
Filter by price
Top rated products
-
-
-
-
-
Head and neck squamous cell carcinoma (LA-HNSCC and Metastatic HNSCC)–Tumour Deck $11,800.00 – $20,000.00
Product categories
- Central Nervous System 7
- Inflammatory 1
- Genetic Disorders 1
- Head and Neck Cancers 2
- Renal Diseases / Nephrology 6
- HER-Low Status in Cancer 4
- Endocrinology 1
- Pipeline Analytics Report 2
- Disease Competitive Landscape Monitoring 3
- Metabolic Disorders 1
- Therapeutic Area 23
- Musculoskeletal Diseases 1
- Oncology 6
- Hematology 3
- Market Forecast 22
- Respiratory Diseases 1
- Ophthalmology 1
- Orthopedics 1